Huafu Securities released a research report on April 28th, giving a buy rating to Hunan Jiudian Pharmaceutical (300705.SZ) with a target price of 44.9 yuan. The main reasons for the rating include: 1) steady growth in each business in 2023, and orderly advancement of the plastering line; 2) formulation: continuous development of OTC, inclusion of ketorolac tromethamine in medical insurance, and continuous leverage of solid oral formulations through volume procurement; 3) raw materials: the company has many varieties, mature technology and cost advantages, and some products lead the market share; 4) rich plastering line, and will soon usher in a harvest period. (Daily Economic News)
华福证券4月28日发布研报称，给予九典制药（300705.SZ）买入评级，目标价格为44.9元。评级理由主要包括：1）2023年各业务稳健增长，贴膏管线有序推进；2）制剂：OTC持续开拓，酮洛芬纳入医保，固体口服制剂持续借助集采放量；3）原辅料：公司品种众多、工艺成熟具备成本优势、部分产品市场率领先；4）贴膏管线丰富，即将迎来收获期。（每日经济新闻）
Huafu Securities released a research report on April 28 stating that it gave Jiudian Pharmaceutical (300705.SZ) a purchase rating, and the target price was 44.9 yuan. The main reasons for the rating include: 1) the steady growth of various businesses in 2
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.